All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Exenatide: A new promising antidiabetic agent

Author(s): CK Chakraborti
Kanak Manjari Institute of Pharmaceutical Sciences, Chhend, Rourkela-769 015, India

Correspondence Address:
C K Chakraborti Kanak Manjari Institute of Pharmaceutical Sciences, Chhend, Rourkela-769 015 India E-mail: [email protected]


Exenatide is a unique agent which can effectively control blood glucose levels in type 2 diabetes mellitus without producing dangerous adverse effects. In addition, it can lower body weight which is very essential for the treatment of obese type 2 diabetes mellitus patients. Since it can delay the destruction of islet beta-cells, type 2 diabetes mellitus patients are not rapidly converted to type 1 diabetes mellitus and ultimately appearance of complications of the disease is halted or delayed. Its long-acting-release formula, which would be used once per week, simultaneously retaining all the properties of twice-daily subcutaneous administration, is undergoing clinical trial. This drug is considered as an adjunct to metformin/sulfonylureas/insulin.

Full-Text | PDF

 
 
List of Supporting Conferences